一般社団法人日本呼吸器学会 公式サイト
日本呼吸器学会英文誌 Respiratory Investigation
日本呼吸器学会誌 増刊号 学術講演会プログラム 抄録集 検索用
日本呼吸器学会誌 増刊号 学術講演会プログラム 抄録集 全文PDF

Abstract

Full Text of PDF Full Text of PDF (868k)
Article in Japanese

Case Report

A case of thymoma remarkably responded to fifth-line chemotherapy with CAMP therapy

Keisuke Watanabea  Masaharu Shinkaia  Hideto Gotoa  Sumiko Yoshikawaa  Nobuhiro Yamaguchia  Yuu Haraa,b  Yusuke Moriyamaa  Yoshiaki Ishigatsuboc  Takeshi Kanekoa 

aRespiratory Disease Center, Yokohama City University Medical Center
bDivision of Infectious Diseases and Pulmonary Medicine, Department of Internal Medicine 2, National Defense Medical College
cDepartment of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine

ABSTRACT

A 67-year-old woman was diagnosed with thymoma (WHO classification type B1, Masaoka clinical stage IVa) in October 2008. She received chemotherapy with cisplatin+doxorubicin+vincristine+cyclophosphamide, carboplatin+paclitaxel, carboplatin+etoposide and docetaxel. But in June 2010, chest CT showed that primary lesion and pleural dissemination had regrown, and she was admitted to receive fifth-line chemotherapy with cisplatin+doxorubicin+metylprednisolone (CAMP therapy). Four cycles of CAMP therapy were introduced from June 2010, and chest CT revealed remarkable efficacy of the treatment. Moreover, toxicity was mild and well tolerable. To control disease progress in this patient, we considered it effective to continue chemotherapy as long as we could. It is possible that CAMP therapy is one of the effective candidates for salvage chemotherapy regimen in thymoma patients.

KEYWORDS

Thymoma  Chemotherapy  CAMP therapy 

Received 12 Aug 2011 / Accepted 27 Jan 2012

AJRS, 1(5): 399-403, 2012

Google Scholar